Griffith University has launched two cancer research centres backed by $4.6 million in funding from the Australian Cancer Research Foundation (ACRF).

A $2 million grant from the ACRF will fund a transformative compound management platform within the new ACRF Centre for Compound Management and Logistics at Compounds Australia – Australia’s only dedicated compound management facility.

Griffith Institute for Drug Discovery (GRIDD) Director Professor Katherine Andrews said Compounds Australia greatly appreciated the funding that would enhance this critical national research infrastructure and accelerate drug discovery and examination of diseases at the molecular level.

In another Australian-first, the Institute for Glycomics has launched the ACRF International Centre for Cancer Glycomics with at $2.6 million ACRF grant, which is dedicated to deciphering the cancer glyco-code. The team of glycomics experts will work with surgeons, radiologists, scientists, and high-risk cancer clinics to develop early markers in high-risk cohorts and therapeutics based on inhibition of relevant protein targets.

Advanced mass spectrometry equipment forms the centrepiece of the ACRF International Centre for Cancer Glycomics, including the Orbitrap Eclipse Tribrid MS and the Hyperion Imaging Mass CyTOF.